- Pure Extracts (PULL) and Psyence Group (PSYG) have formed a JV for psychedelic medicinal mushroom extracts
- The Pure Psyence partnership will develop naturally-derived psilocybin extracts and psilocybin formulations for the treatment of mental health
- The companies are confident that their combined expertise will facilitate production on a commercial pharmaceutical scale
- The Psyence Group uses natural psilocybin to treat psychological trauma and its mental health consequences
- Pure Extracts is a plant-based extraction company based in Whistler, British Columbia
- Psyence Group (PSYG) is unchanged trading at $0.20 per share
- Pure Extracts (PULL) is down by 3.33 per cent trading at $0.29 per share
Pure Extracts (PULL) and Psyence Group (PSYG) have formed a JV for psychedelic medicinal mushroom extracts.
The Pure Psyence partnership will develop naturally-derived psilocybin extracts and psilocybin formulations for the treatment of mental health and psychological trauma.
The work will leverage Psyence’s in-house psilocybin mushrooms alongside Pure Extracts’ extraction expertise to reach production on a commercial pharmaceutical scale.
Psyence built and operates one of the world’s first federally licensed commercial psilocybin cultivation and production facilities. Located in the Kingdom of Lesotho, the facility was designed and constructed to The British Standards Institute and Good Manufacturing Practice standards.
Ben Nikolaevsky, Pure Extracts’ CEO, remarked,
“Pure Psyence sits at the intersection of evidence-based science and nature. The researchers, scientists and physicians at Pure Psyence will now be uniquely positioned to bring psilocybin whole mushroom in measurable pharmaceutical dosages to market.”
The Psyence Group uses natural psilocybin to treat psychological trauma and its mental health consequences.
Pure Extracts is a plant-based extraction company based in Whistler, British Columbia.
Psyence Group (PSYG) is unchanged trading at $0.20 per share as of 10:21 am ET.
Pure Extracts (PULL) is down by 3.33 per cent trading at $0.29 per share as of 10:01 am ET.
